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Deoxycytidine kinase (dCK) is a critical enzyme for activation of anticancer nucleoside analogs. Its
activity is controlled via Ser-74 phosphorylation. Here, we investigated which Ser/Thr phosphatase
dephosphorylates Ser-74. In cells, the PP1/PP2A inhibitor okadaic acid increased both dCK activity
and Ser-74 phosphorylation at concentrations reported to speciﬁcally target PP2A. In line with this,
puriﬁed PP2A, but not PP1, dephosphorylated recombinant pSer-74-dCK. In cell lysates, the Ser-74-
dCK phosphatase activity was found to be latent, Mn2+-activated, responsive to PP2A inhibitors, and
diminished after PP2A-immunodepletion. Use of siRNAs allowed concluding deﬁnitively that PP2A
constitutively dephosphorylates dCK in cells and negatively regulates its activity.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Deoxycytidine kinase (dCK) converts deoxycytidine, deoxygua-
nosine and deoxyadenosine into their monophosphate form with
ATP or UTP as phosphoryl donor. This reaction is the ﬁrst and
rate-limiting step of the deoxyribonucleoside salvage pathway that
supplies cells with precursors of DNA as an alternative to de novo
synthesis [1]. In addition, dCK phosphorylates and thereby acti-
vates several anticancer and antiviral nucleoside analogs, such as
ﬂudarabine, cytarabine, gemcitabine, zalcitabine and lamivudine
[2,3].
Given the essential physiological and pharmacological role of
dCK, identiﬁcation of the mechanisms that regulate its activity is
of particular interest. The ﬁrst mechanism reported to control
dCK activity was retro-inhibition by dCTP, although its physiolog-
ical relevance is questionable [4–6]. Thereafter, several studies[7–10] suggested that dCK activity could be regulated by post-
translational modiﬁcation, which was deﬁnitively conﬁrmed by
our group. We established that dCK is a phosphoprotein containing
at least four phosphorylation sites: Thr-3, Ser-11, Ser-15 and Ser-
74, the latter being the major phosphorylated residue and the only
one to play a role in the regulation of dCK activity [11]. Further-
more, we found that increase in dCK activity induced by genotoxic
treatments, such as etoposide, aphidicolin, UV-irradiation, was cor-
related to an increase of Ser-74 phosphorylation, whereas decrease
of its activity induced by osmotic stress was related to Ser-74
dephosphorylation [11,12]. Insight into the mechanism by which
Ser-74 phosphorylation modiﬁes dCK activity has recently been
provided through structural studies of Hazra et al. [13], who pro-
pose that phosphorylation of Ser-74 favors the adoption by dCK
of an open conformation more conducive for binding of nucleoside
and release of the nucleoside monophosphate product.
The ﬁnding of the phosphorylation of dCK at Ser-74 raised the
question of which protein kinase(s) and phosphatase(s) directly
phosphorylate(s) or dephosphorylate(s) this residue. Casein kinase
1d was shown to be able to phosphorylate dCK on Ser-74 in vitro,
but would not be responsible for its in vivo phosphorylation [14].
In contrast, the DNA-damage-response kinase ATM (ataxia telangi-
ectasia mutated) was found to phosphorylate Ser-74 in vitro, but
also in vivo, which was also associated with a role of dCK in the
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phosphatase (PP) that dephosphorylates Ser-74 in intact cells, its
responsiveness to okadaic acid (OA) has been established. Indeed,
this PP inhibitor increased dCK activity [16] and Ser-74 phosphor-
ylation [14] in cultured cells.
Ser/Thr speciﬁc protein phosphatases comprise three structur-
ally unrelated superfamilies and have been implicated in the regu-
lation of many cell events [17,18]. The vast majority of Ser and Thr
dephosphorylations in eukaryotic cells are catalyzed by members
of the PPP (phosphoprotein phosphatases) and PPM (protein
phosphatase metal) families. PPMs are Mg2+/Mn2+-dependent
monomeric enzymes with PP2C phosphatases as the major repre-
sentatives and are insensitive to OA inhibition. PPPs comprise the
large families of multimeric Ser/Thr protein phosphatase 1 (PP1),
Ser/Thr protein phosphatase 2A (PP2A) and PP2B (calcineurin)
phosphatases, as well as the more recently identiﬁed PP4, PP5,
PP6 and PP7 phosphatases, which are expressed at relatively low
abundance. PP4 and PP6 are sometimes referred to as PP2A-like
phosphatases due to their high structural homology with PP2A
and similar sensitivities to pharmacological phosphatase inhibi-
tors. Among Ser/Thr phosphatases, PP2A is potently inhibited by
OA in the low nanomolar range, while PP1 is around 100 times less
sensitive. In contrast, PP4 and PP6 have similar IC50 values for OA
than PP2A [19]. In the present study, we sought to determine
which OA-sensitive PP is responsible for Ser-74 dephosphorylation
and hence is involved in the regulation of dCK activity.2. Material and methods
2.1. Materials
Dulbecco’s Modiﬁed Eagle Medium (DMEM), ultraglutamine, fe-
tal calf serum (FCS) and penicillin–streptomycin were purchased
from Lonza. RPMI-1640 and all tissue culture reagents were from
Gibco/Invitrogen. [5-3H]-deoxycytidine (30 Ci/mmol) was from
Moravek Biochemicals. OA was from Enzo Life Sciences. Anti-phos-
pho-Ser-74 and anti-dCK antibodies were generated as described
previously [11]. Anti-poly(His) monoclonal antibody, protein A Se-
pharose beads and NAP-5 columns were from GE Healthcare. Anti-
PP1c (sc-7482), anti-PP2Ac (sc-166034) antibodies and fostriecin
(Fos) were from Santa Cruz Biotechnology. Fluorescent secondary
antibodies IRDye680 or IRDye800 and Odyssey blocking buffer
were from Li-COR Biosciences. Catalytic subunit of PP2A (speciﬁc
activity: 10 U/mg), puriﬁed from beef heart according to Cohen
et al. [20], and GST-tagged catalytic subunit of PP1 (speciﬁc activ-
ity: 8 U/mg), puriﬁed after overexpression in Escherichia coli, were
kindly provided by Prof. M. Rider (de Duve Institute, Brussels, Bel-
gium). Other chemicals, materials and reagents were from Sigma–
Aldrich, Merck Biosciences or Bio-Rad Laboratories.
2.2. Cell culture and incubation
CCRF-CEM cells and HEK293T cells that stably express human
dCK were cultured as described [11,14]. EBV-transformed lympho-
blasts GM0536 (ATM+/+) and GM1526 (ATM/), purchased from
The NIGMS human Mutant Cell Repository, were maintained in
RPMI-1640 with Glutamax supplemented with 15% heat-inacti-
vated FCS. OA was dissolved in DMSO and equal amounts of DMSO
were added in control cells.
2.3. Preparation of cell lysates and dCK assay
CCRF-CEM, GM0536, GM1526 or HEK293T cell extracts were
prepared as previously described [11,16]. dCK activity was mea-
sured with a radiochemical assay as described in [16] using10 lM [5-3H]deoxycytidine and 5 mM ATP as substrates and 30–
100 lg of cellular protein or 0.05–0.1 lg of recombinant dCK. The
protein content of samples was measured by the method of Brad-
ford [21], with BSA as a standard.
2.4. Protein phosphatase treatment of puriﬁed recombinant dCK
Recombinant dCK (0.5 lg) overexpressed in HEK293T cells and
puriﬁed as reported previously [11] was incubated at 30 C in 50 ll
of a reaction mixture containing 50 mM Tris–HCl, pH 7.6, 2 mM
dithiothreitol and 2 mM MnCl2 in the absence or in the presence
of 0.2 U of puriﬁed catalytic subunit of PP1 (PP1c) or catalytic sub-
unit of PP2A (PP2Ac). After 40 min of incubation, aliquots (0.1 lg of
protein) were taken for dCK assay and western blot analysis.
2.5. Ser-74-dCK phosphatase assay in cell lysates
For analysis of dCK dephosphorylation at Ser-74 and dCK inac-
tivation in cell lysates, cell extracts were prepared in a phosphatase
assay buffer (50 mM Tris–HCl, pH 7.6, 5 mM dithiothreitol, 0.5%
Nonidet P-40, 0.1 mM EDTA, 20% glycerol, 0.5 mM p-toluenesulfo-
nyl ﬂuoride, 5 mM benzamidine, and 5 lg/ml leupeptin and anti-
pain). After centrifugation, supernatants were ﬁltered on NAP-5
columns and 300 lg of ﬁltered protein were then incubated at
37 C for 90 min, as such or in the presence of 0.5 lg of puriﬁed re-
combinant dCK [11]. The reaction was started by the addition of
Mn2+ at the indicated concentration. At time zero and after
90 min of incubation, aliquots were taken for analysis of dCK phos-
phorylation at Ser-74 and activity.
2.6. PP2A immunoprecipitation
For PP2A immunoprecipitation, protein A Sepharose beads
(60 ll) were incubated with 9 lg of anti-PP2Ac antibody on a rock-
er for 1 h at 4 C. The beads were then washed twice with the phos-
phatase assay buffer and incubated overnight with 900 lg of
protein extract at 4 C. After centrifugation, the supernatant was
used for Ser-74-dCK phosphatase analysis as described above.
2.7. RNA interference
HEK293T cells stably expressing dCK were plated in 10 cm-
dishes (0.6  106 cells/dish) and transfected on the following day
using negative control small interfering RNA (siRNA) (non-target-
ing pool: # D-001810-10, from Dharmacon), 50 nM PP2Ac siRNA
(directed against the PP2Ac alpha isoform: # L-003598-010005,
from Dharmacon) or 50 nM pan PP1c siRNA (# sc-43545, from San-
ta Cruz Biotechnology) and 20 ll Lipofectamin 2000 (Invitrogen),
according to the manufacturer’s instructions. After 72 h, the cells
were washed with cold PBS and cell extracts were prepared as de-
scribed in [16]. After centrifugation, supernatants were used for
dCK activity assay and western blot analysis.
2.8. Immunoblot analysis
Aliquots containing 40–100 lg of cell protein or 0.05–0.1 lg of
recombinant dCK were subjected to SDS–PAGE electrophoresis in
12% (w/v) polyacrylamide gels and transferred to low ﬂuorescence
PVDF immobilon-FL membranes (Millipore). After transfer, PVDF
membranes were blocked for 1 h at room temperature in Odyssey
blocking buffer and then probed overnight with either anti-phos-
pho-Ser-74 (1/1000), anti-poly(His) (1/4000), anti-dCK (1/500),
anti-PP1c (1/1000), anti-PP2Ac (1/1000), or anti-b-actin (1/
10,000). After washing in PBS-T (Tween 0.1%), the membranes
were incubated for 1 h at room temperature with the appropriate
ﬂuorescent secondary antibody IRDye680 or IRDye800
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0.1% Tween and 0.1% SDS. After washing, the membranes were
scanned with the Odyssey Infrared Imaging System (Li-COR). Rep-
resentative immunoblots are shown. When indicated, ﬂuorescence
intensities have been used to quantify dCK phosphorylation or
expression [22].
2.9. Statistical analysis
dCK activities are the means ± S.E.M. of at least three indepen-
dent experiments. Signiﬁcance was analyzed by paired Student’s
t-tests. Changes were considered signiﬁcantly different when
P < 0.05.
3. Results and discussion
Our previous ﬁndings that dCK activity [16] and dCK phosphor-
ylation at Ser-74 [14] were augmented in intact cells after treat-
ment with 500 nM OA, a cell-permeable PP1/PP2A inhibitor, and
the fact that puriﬁed PP2A inactivated dCK in cell lysates [16] led
us to postulate that PP2A was involved in the in vivo regulation
of dCK activity. Though OA inhibits both PP1 and PP2A, it has sub-
stantial preference in vitro for PP2A (IC50 = 0.1 nM) over PP1
(IC50 = 10 nM) [19]. Its selectivity for PP2A has also been demon-
strated in vivo in intact cells in which 100 nM OA has been shown
to inhibit PP2A without affecting PP1 activity [23]. Therefore, we
sought to examine thoroughly the dose–response effect of OA on
both dCK phosphorylation at Ser-74 and dCK activity. Analyses
were performed after a 4 h-incubation in CCRF-CEM cells in which
phosphorylation of dCK at Ser-74 can be easily detected by western
blot [11]. Increase in Ser-74 phosphorylation (Fig. 1A) and in dCK
activity (Fig. 1B) was already noticed at 25 nM OA, while maximal
Ser-74 phosphorylation level and dCK activity were reached at
100 nM. These results suggested that PP2A or a PP2A-like enzyme,
rather than PP1, was involved in the control of Ser-74
phosphorylation.
In cells, increase of Ser-74 phosphorylation can result from inhi-
bition of a dCK phosphatase or from activation of a dCK kinase.0 25 50 100 250 5000
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Fig. 1. Dose–response effects of OA on Ser-74-dCK phosphorylation and activity.
CCRF-CEM cells were incubated for 4 h with increasing concentrations of OA. Cell
lysates were analyzed for (A) dCK phosphorylation at Ser-74 and (B) dCK activity
(mean ± S.E.M. of 5 independent experiments). Signiﬁcance relative to the absence
of OA: ⁄P < 0.05; ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001.Nowadays, ATM is the only protein kinase known to phosphorylate
dCK at Ser-74 in vivo [15]. To verify that the increase of Ser-74
phosphorylation induced by OA was not due to the indirect activa-
tion of ATM, we compared the effect of OA in ATM proﬁcient
(GM0536) and deﬁcient (GM1526) lymphoblastoid cell lines. We
found that OA induced similar dCK activation in both cell lines,
either at 100 (not shown) or at 500 nM (Fig. 2A and B). These re-
sults indicate that increase in Ser-74 phosphorylation induced by
OA cannot be explained by ATM activation, which is consistent
with the ﬁnding that OA, though inducing autophosphorylation
of ATM on Ser-1981, does not increase its kinase activity [24].
Interestingly, these data also indicate that a kinase different from
ATM can phosphorylate dCK at Ser-74 at least in basal conditions,
which deserves further investigations.
To corroborate the hypothesis that PP2A rather than PP1 is in-
volved in Ser-74 dephosphorylation, we compared the ability of
puriﬁed catalytic subunits of PP1 (PP1c) and PP2A (PP2Ac) to
dephosphorylate Ser-74-dCK. Recombinant dCK overexpressed in
HEK293T cells, which is highly phosphorylated at Ser-74 [11],
was used as substrate. Incubation of the latter with PP1c induced
neither Ser-74 dephosphorylation (Fig. 3A) nor decrease of its
activity (Fig. 3B) in comparison with the control condition,
whereas PP2Ac used at the same speciﬁc activity as PP1c decreased
Ser-74 phosphorylation (Fig. 3A) by 70.9 ± 3.9% (n = 3) and dCK
activity (Fig. 3B) by 75.2 ± 7.1% (n = 5). We veriﬁed that PP1c was
active by checking its capacity to dephosphorylate histone H1
32P-prelabeled by protein kinase A as described in [19] (not
shown). We conclude that PP2Ac, but not PP1c, dephosphorylates
dCK at Ser-74 in vitro.
The next step was to analyze Ser-74-dCK phosphatase activity
from cell lysates. For this purpose, CCRF-CEM cell extracts were
prepared in a buffer containing no phosphatase inhibitors and
then gel-ﬁltered to remove small molecular weight molecules.
First, we examined the ability of a cell lysate to dephosphorylate
the recombinant dCK. Quite unexpectedly, we found that neither
the phosphorylation of recombinant dCK at Ser-74 (Fig. 4A) nor0
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Fig. 2. Comparison of Ser-74 phosphorylation and dCK activation induced by OA in
GM0536 (ATM+/+) and GM1526 (ATM/) cells. Cells were incubated for 4 h in the
absence or the presence of 500 nM OA. Cell lysates were analyzed for (A) dCK
phosphorylation at Ser-74 and (B) dCK activity (mean ± S.E.M. of 4 independent
experiments). Signiﬁcance relative to the absence of OA: ⁄P < 0.05. Increase of dCK
activity induced by OA in ATM (+/+) cells was 2.86 ± 0.37-fold in comparison with
2.5 ± 1.18-fold in ATM (/) cells.
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Fig. 3. PP2Ac, but not PP1c, dephosphorylates dCK at Ser-74 in vitro. Recombinant
dCK, was incubated at 30 C in the absence or in the presence of puriﬁed PP1c or
PP2Ac, as described in the Methods. (A) dCK phosphorylation at Ser-74 and (B) dCK
activity (mean ± S.E.M. of 5 independent experiments) were measured after 40 min
of treatment. Signiﬁcance relative to the control condition: ⁄⁄P < 0.01.
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bation at 37 C in the presence of the cell lysate, unless Mn2+ was
added in the assay mixture at a concentration exceeding 0.1 mM.
Similar results were obtained with unﬁltered cell lysates (not
shown), conﬁrming that Ser-74-dCK phosphatase requires Mn2+0 0 0.1 0.2 0.5 1 2 5
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Fig. 4. Mn2+ activates Ser-74-dCK phosphatase activity in cell lysates. Recombinant
dCK was incubated at 37 C in the presence of 300 lg of CCRF-CEM cell lysate
protein, in the absence or in the presence of MnCl2 at increasing concentrations. (A)
Phosphorylation of dCK at Ser-74 and (B) dCK activity (mean ± S.E.M. of 3
independent experiments) were analyzed before (0 min) and after 90 min of
incubation. Activity of dCK at 0 min was 197 ± 35 nmol/min/mg protein. Signiﬁ-
cance relative to the absence of MnCl2: ⁄P < 0.05; ⁄⁄P < 0.01.to be active. Analysis of the effect of other divalent metal showed
that Fe2+ or Mg2+ could replace Mn2+ albeit with a lower efﬁciency
(not shown). Following these experiments, 2 mM Mn2+ was in-
cluded in all in vitro Ser-74-dCK phosphatase assays. To verify
whether this Mn2+-activated Ser-74-dCK phosphatase could be
PP2A, we analyzed whether PP2A inhibitors could inhibit it. We
found that OA completely prevented dephosphorylation of the re-
combinant dCK (Fig. 5A) by the cell lysate and strongly reduced its
inactivation (Fig. 5B). This allows to exclude the possibility that
Ser-74-dCK phosphatase is a type 2C phosphatase (PP2C), which
is characterized by dependence on divalent cations, but insensitiv-
ity to OA [25,26]. Fostriecin, a highly selective inhibitor of PP2A
[27], also clearly reduced the Mn2+-dependent Ser-74-dCK phos-
phatase activity from cell lysates (Fig. 5A and B).
Although it is generally accepted that PP2A is not dependent on
Mn2+ or other divalent cations for activity, metal ions are required
in the catalysis of PPP phosphatases through the activation of a
water molecule for the dephosphorylation reaction [17]. In addi-
tion, some studies reported that PP2A can exist in a latent form,
which can be activated in vitro by treatment with Mn2+ [28–31].
Inactivation of PP2A, which has especially been observed after pro-
longed storage but also under other conditions, was explained by
the loss of metal ions from its catalytic site. The Mn2+-independent
PP2Ac has indeed been reported to be a Zn2+- and Fe2+-metalloen-
zyme [30]. In our hands, the Mn2+-dependency of Ser-74-dCK
phosphatase activity was not correlated to the storage and was
not due to gel-ﬁltration, but was present as soon as cell lysates
were prepared.
To further conﬁrm that Ser-74-dCK phosphatase is PP2A, we
compared Ser-74-dCK phosphatase activity of CCRF-CEM cell ly-
sates from which PP2A had been, or not, removed by immunopre-
cipitation. As observed with recombinant dCK, dephosphorylation
(Fig. 6A) and inactivation (Fig. 6B) of endogenous dCK in whole cell
lysates were strongly inhibited by OA and fostriecin. Dephospho-
rylation and inactivation of dCK were also reduced following
immunodepletion of PP2A, showing that Ser-74-dCK phosphatasepS74-dCK
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Fig. 5. Ser-74-dCK phosphatase from cell lysate is sensitive to PP2A inhibitors.
Recombinant dCK was incubated at 37 C in the presence of 300 lg of CCRF-CEM
cell lysate protein, in the absence or in the presence of 500 nM OA or 500 nM
fostriecin (Fos). Mn2+ was present at 2 mM. (A) Phosphorylation of dCK at Ser-74
and (B) dCK activity (mean ± S.E.M. of 3 independent experiments) were analyzed
before (0 min) and after 90 min of incubation. Signiﬁcance relative to the absence of
PP2A inhibitors: ⁄⁄P < 0.01.
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Addition of OA or fostriecin to PP2A-immunodepleted cell lysates
inhibited more completely the dephosphorylation of dCK at Ser-
74 and its inactivation. This indicates that Ser-74-dCK phosphatase
activity was not completely eliminated by PP2A immunodepletion,
which could be explained by residual PP2Ac presence in the super-
natant (Fig. 6A). In contrast to what was observed after PP2A
immunodepletion, PP1 immunodepletion did not inﬂuence the
dephosphorylation of Ser-74-dCK and the inactivation of dCK in
CCRF-CEM cell lysates (not shown).
To deﬁnitively prove that Ser-74-dCK is a physiological sub-
strate for PP2A and not for PP1, we used siRNA to down-regulate
the expression of the catalytic subunit of PP2A or PP1. As previ-
ously described, we used HEK293T cells stably expressing dCK as
experimental model for siRNA transfection [14]. Analysis of PP2Ac
and PP1c by immunoblotting showed that after a 72 h-transfec-
tion, PP2Ac and PP1c siRNA decreased PP2Ac and PP1c protein lev-
els by 73.3 ± 1.8 and 82.9 ± 5.5% (n = 4), respectively. Down-
regulation of PP2Ac was accompanied by a signiﬁcant increase of
both dCK phosphorylation at Ser-74 and dCK activity, whereas
down-regulation of PP1c did not inﬂuence any of them (Fig. 7A
and B). These results demonstrate that PP2A is a physiological pro-
tein phosphatase for dCK phosphorylated at Ser-74 (pSer-74-dCK).
In conclusion, the present study shows that PP2A is a negative
regulator of dCK activity in cells and so adds new information
about the signaling pathway that controls dCK activity in vivo.
Use of PP2A inhibitors could thus be considered as a potential
strategy to enhance dCK activity and hence the activation and clin-
ical efﬁcacy of anticancer nucleoside analogs that are substrates of
dCK, especially as PP2A inhibitors may be, under certain condi-tions, promising therapeutic drugs for the treatment of cancer
[32–34].
Acknowledgements
This work was supported by Grants from the Belgian Fonds Na-
tional de la Recherche Scientiﬁque (Télévie, FRSM, FRIA), by the
Interuniversity Attraction Poles Program-Belgian Science Policy,
the Center of excellence DIANE programme of the RégionWalonne,
and by private foundations: Jacques Goor and Salus Sanguinis.
References
[1] Arner, E.S. and Eriksson, S. (1995) Mammalian deoxyribonucleoside kinases.
Pharmacol. Ther. 67, 155–186.
[2] Van Rompay, A.R., Johansson, M. and Karlsson, A. (2003) Substrate speciﬁcity
and phosphorylation of antiviral and anticancer nucleoside analogues by
human deoxyribonucleoside kinases and ribonucleoside kinases. Pharmacol.
Ther. 100, 119–139.
[3] Galmarini, C.M., Mackey, J.R. and Dumontet, C. (2002) Nucleoside analogues
and nucleobases in cancer treatment. LANCET Oncol. 3, 415–424.
[4] Sarup, J.C., Johnson, M.A., Verhoef, V. and Fridland, A. (1989) Regulation of
purine deoxynucleoside phosphorylation by deoxycytidine kinase from
human leukemic blast cells. Biochem. Pharmacol. 38, 2601–2607.
[5] Datta, N.S., Shewach, D.S., Hurley, M.C., Mitchell, B.S. and Fox, I.H. (1989)
Human T-lymphoblast deoxycytidine kinase: puriﬁcation and properties.
Biochemistry 28, 114–123.
[6] Amsailale, R., Van Den Neste, E., Arts, A., Starczewska, E., Bontemps, F. and
Smal, C. (2012) Phosphorylation of deoxycytidine kinase on Ser-74: impact on
kinetic properties and nucleoside analog activation in cancer cells. Biochem.
Pharmacol. 84, 43–51.
[7] Sasvari-Szekely, M., Spasokoukotskaja, T., Szoke, M., Csapo, Z., Turi, A., Szanto,
I., et al. (1998) Activation of deoxycytidine kinase during inhibition of DNA
synthesis by 2-chloro-20-deoxyadenosine (Cladribine) in human lymphocytes.
Biochem. Pharmacol. 56, 1175–1179.
[8] Spasokoukotskaja, T., Sasvari-Szekely, M., Keszler, G., Albertioni, F., Eriksson, S.
and Staub, M. (1999) Treatment of normal and malignant cells with nucleoside
analogues and etoposide enhances deoxycytidine kinase activity. Eur. J. Cancer
35, 1862–1867.
732 R. Amsailale et al. / FEBS Letters 588 (2014) 727–732[9] Csapo, Z., Keszler, G., Safrany, G., Spasokoukotskaja, T., Talianidis, I., Staub, M.,
et al. (2003) Activation of deoxycytidine kinase by gamma-irradiation and
inactivation by hyperosmotic shock in human lymphocytes. Biochem.
Pharmacol. 65, 2031–2039.
[10] Keszler, G., Spasokoukotskaja, T., Csapo, Z., Talianidis, I., Eriksson, S., Staub, M.,
et al. (2004) Activation of deoxycytidine kinase in lymphocytes is calcium
dependent and involves a conformational change detectable by native
immunostaining. Biochem. Pharmacol. 67, 947–955.
[11] Smal, C., Vertommen, D., Bertrand, L., Ntamashimikiro, S., Rider, M.H., Van Den
Neste, E., et al. (2006) Identiﬁcation of in vivo phosphorylation sites on human
deoxycytidine kinase. Role of Ser-74 in the control of enzyme activity. J. Biol.
Chem. 281, 4887–4893.
[12] Smal, C., Van Den Neste, E., Maerevoet, M., Poire, X., Theate, I. and Bontemps, F.
(2007) Positive regulation of deoxycytidine kinase activity by phosphorylation
of Ser-74 in B-cell chronic lymphocytic leukaemia lymphocytes. Cancer Lett.
253, 68–73.
[13] Hazra, S., Szewczak, A., Ort, S., Konrad, M. and Lavie, A. (2011) Post-
translational phosphorylation of serine 74 of human deoxycytidine kinase
favors the enzyme adopting the open conformation making it competent for
nucleoside binding and release. Biochemistry 50, 2870–2880.
[14] Smal, C., Vertommen, D., Amsailale, R., Arts, A., Degand, H., Morsomme, P.,
et al. (2010) Casein kinase 1delta activates human recombinant deoxycytidine
kinase by Ser-74 phosphorylation, but is not involved in the in vivo regulation
of its activity. Arch. Biochem. Biophys. 502, 44–52.
[15] Yang, C., Lee, M., Hao, J., Cui, X., Guo, X., Smal, C., et al. (2012) Deoxycytidine
kinase regulates the G2/M checkpoint through interaction with cyclin-
dependent kinase 1 in response to DNA damage. Nucleic Acids Res. 40,
9621–9632.
[16] Smal, C., Cardoen, S., Bertrand, L., Delacauw, A., Ferrant, A., Van den Berghe, G.,
et al. (2004) Activation of deoxycytidine kinase by protein kinase inhibitors
and okadaic acid in leukemic cells. Biochem. Pharmacol. 68, 95–103.
[17] Shi, Y. (2009) Serine/threonine phosphatases: mechanism through structure.
Cell 139, 468–484.
[18] Brautigan, D.L. (2013) Protein Ser/Thr phosphatases – the ugly ducklings of
cell signalling. FEBS J. 280, 324–345.
[19] Swingle, M., Ni, L. and Honkanen, R.E. (2007) Small-molecule inhibitors of ser/
thr protein phosphatases: speciﬁcity, use and common forms of abuse.
Methods Mol. Biol. 365, 23–38.
[20] Cohen, P., Alemany, S., Hemmings, B.A., Resink, T.J., Stralfors, P. and Tung, H.Y.
(1988) Protein phosphatase-1 and protein phosphatase-2A from rabbit
skeletal muscle. Methods Enzymol. 159, 390–408.
[21] Bradford, M.M. (1976) A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye binding.
Anal. Biochem. 72, 248–254.[22] Smal, C., Ntamashimikiro, S., Arts, A., Van Den Neste, E. and Bontemps, F.
(2010) Inﬂuence of phosphorylation of THR-3, SER-11, and SER-15 on
deoxycytidine kinase activity and stability. Nucleosides, Nucleotides Nucleic
Acids 29, 404–407.
[23] Favre, B., Turowski, P. and Hemmings, B.A. (1997) Differential inhibition and
posttranslational modiﬁcation of protein phosphatase 1 and 2A in MCF7 cells
treated with calyculin-A, okadaic acid, and tautomycin. J. Biol. Chem. 272,
13856–13863.
[24] Goodarzi, A.A., Jonnalagadda, J.C., Douglas, P., Young, D., Ye, R., Moorhead, G.B.,
et al. (2004) Autophosphorylation of ataxia-telangiectasia mutated is
regulated by protein phosphatase 2A. EMBO J. 23, 4451–4461.
[25] Cohen, P. (1989) The structure and regulation of protein phosphatases. Annu.
Rev. Biochem. 58, 453–508.
[26] Bialojan, C. and Takai, A. (1988) Inhibitory effect of a marine-sponge toxin,
okadaic acid, on protein phosphatases. Speciﬁcity and kinetics. Biochem. J.
256, 283–290.
[27] Walsh, A.H., Cheng, A. and Honkanen, R.E. (1997) Fostriecin, an antitumor
antibiotic with inhibitory activity against serine/threonine protein
phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A. FEBS
Lett. 416, 230–234.
[28] Cai, L., Chu, Y., Wilson, S.E. and Schlender, K.K. (1995) A metal-dependent form
of protein phosphatase 2A. Biochem. Biophys. Res. Commun. 208, 274–279.
[29] Nishito, Y., Usui, H., Tanabe, O., Shimizu, M. and Takeda, M. (1999)
Interconversion of Mn(2+)-dependent and -independent protein
phosphatase 2A from human erythrocytes: role of Zn(2+) and Fe(2+) in
protein phosphatase 2A. J. Biochem. 126, 632–638.
[30] Nishito, Y., Usui, H., Shinzawa-Itoh, K., Inoue, R., Tanabe, O., Nagase, T., et al.
(1999) Direct metal analyses of Mn2+-dependent and -independent protein
phosphatase 2A from human erythrocytes detect zinc and iron only in the
Mn2+-independent one. FEBS Lett. 447, 29–33.
[31] Longin, S., Jordens, J., Martens, E., Stevens, I., Janssens, V., Rondelez, E., et al.
(2004) An inactive protein phosphatase 2A population is associated with
methylesterase and can be re-activated by the phosphotyrosyl phosphatase
activator. Biochem. J. 380, 111–119.
[32] McConnell, J.L. and Wadzinski, B.E. (2009) Targeting protein serine/threonine
phosphatases for drug development. Mol. Pharmacol. 75, 1249–1261.
[33] Kalev, P. and Sablina, A.A. (2011) Protein phosphatase 2A as a potential target
for anticancer therapy. Anticancer Agents Med. Chem. 11, 38–46.
[34] Lambrecht, C., Haesen, D., Sents, W., Ivanova, E. and Janssens, V. (2013)
Structure, regulation, and pharmacological modulation of PP2A phosphatases.
Methods Mol. Biol. 1053, 283–305.
